LUNAPHORE-TECHNOLOGIES
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/
The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.
The new Lunaphore SAB will be comprised of the following members:
- Prof. Paolo A. Ascierto, MD
Dr. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC), President of the Fondazione Melanoma Onlus, and of Campania Society of ImmunoTherapy of Cancer (SCITO). He is an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and Associate Editor of Journal of ImmunoTherapy of Cancer. He has been the Principal Investigator in over 100 clinical trials and is the author of more than 450 publications in peer-reviewed journals.
- Dr. Jérôme Galon
Dr. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. Dr. Galon defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. This scientific contribution was acknowledged by many awards such as the William B. Coley Award, the Award from the National Academy of Science, from the National Academy of Medicine, and European Inventor Award 2019. He is the co-founder of HalioDx and the Chairman of its Scientific Council.
“I am excited to have such great experts in I-O join our SAB,” said Dr. Dupouy, CTO at Lunaphore. “Their expertise in the field will be key to focus our research efforts on the most promising I-O applications, as well as to expand our scientific collaborations worldwide.”
"The key for the immune responsiveness is in the tumor microenvironment,” noted Dr. Ascierto. “Lunaphore has a technology which can potentially make such evaluation easier and greatly contribute to the research field of immunotherapy."
“Lunaphore is developing rapid automated staining instruments based on an innovative microfluidic technology with great potential for multiple research applications,” Dr. Galon said. “I look forward to the next generation hyper-plex immunofluorescence instruments.”
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological Breakthroughs12.1.2026 18:00:00 CET | Press release
New AI Agents Trained on Millions of Multimodal Datasets Will Speed up Biomedical Research Throughout the Healthcare Ecosystem; Also Announcing New Anthropic Relationship Owkin, the AI company on a mission to solve the complexity of biology, today announced the launch of its agentic infrastructure for biology, making its best-in-class AI agents available to the healthcare ecosystem. The announcement comes at the JPM Healthcare Conference 2026 and follows Owkin’s recent strategic partnerships and its just-announced integration with Claude for Healthcare and Life Sciences by Anthropic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112461277/en/ Owkin, a 10-year-old AI company with $300 million in funding, is introducing the infrastructure, built on a unique advantage: unparalleled, curated, multimodal patient data from diverse geographies, collected from more than 800 hospitals over a decade. While other companies focus pr
Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences12.1.2026 18:00:00 CET | Press release
First Interoperable AI Agent Trained on Multimodal Patient Data is Accessible Through Model Context Protocol (MCP), Bringing State-of-the-Art Agentic AI to the Healthcare Industry Owkin, an AI company on a mission to solve the complexity of biology, today announced that its interoperable Pathology Explorer AI agent will be included in the launch of Claude for Healthcare and Life Sciences (HCLS) by Anthropic. This marks the first time a highly specialized, world-leading biological agent trained primarily on multimodal patient data is accessible through the Model Context Protocol (MCP) to a broad audience of healthcare and life sciences professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112836381/en/ Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences. The collaboration enables seamless integration of Owkin's advanced pathology analysis capa
Berkshire Hathaway Specialty Insurance Names David Lee Global Chief Human Resources Officer12.1.2026 16:27:00 CET | Press release
Berkshire Hathaway Specialty Insurance (BHSI) today announced the promotion of David Lee to Global Chief Human Resources Officer. “I am thrilled to have David leading our human resources group worldwide,” said Peter Eastwood, President and Chief Executive Officer, BHSI. “An experienced HR practitioner and lifelong student of the profession, his deep expertise, stellar work ethic, and commitment to BHSI values will continue to drive success across our global talent and HR initiatives.” David succeeds Kim Briones, who has led BHSI’s HR group since the company’s founding in 2013 and is retiring from her full-time role. “I want to express my sincere gratitude to Kim for her partnership and friendship over many years and for her outstanding leadership in building our HR function from the ground up,” Peter added. “She has played a pivotal role in growing and developing our company’s greatest asset – our global team of individuals with excellent capabilities and strong character – and in help
Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA12.1.2026 16:00:00 CET | Press release
Collaboration Leverages NVIDIA's Open Models, AI Infrastructure and Expertise to Build Next-Generation Biological Reasoning Models for Drug Development Owkin, an AI company on a mission to solve the complexity of biology, today announced a collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model. The collaboration will leverage NVIDIA's advanced AI computing ecosystem, including the Nemotron family of open models and the NVIDIA NeMo framework to improve the performance, scalability, guardrails, and robustness of Owkin's biological reasoning capabilities to accelerate future breakthroughs in drug discovery and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112573701/en/ Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA. This marks Owkin's first collaboration with NVIDIA and represents a significant milestone in building
SecurityBridge Announces CEO Transition to Accelerate Global Expansion12.1.2026 15:15:00 CET | Press release
SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the appointment of Jesper Zerlang as Chief Executive Officer, effective January 1, 2026. Zerlang transitions from his role as Chairman of the Board, a position he has held for the past 12 months, as the company enters its next phase of international expansion, backed by funds advised by BUBregal Unternehmerkapital (BU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112824449/en/ Jesper Zerlang appointed Chief Executive Officer, SecurityBridge SecurityBridge protects SAP environments for large enterprises by reducing cyber risk across mission-critical SAP landscapes. The company is trusted by global customers to safeguard systems that power core operations, financial processes, supply chains, and digital transformation programs. “SecurityBridge is uniquely positioned at the intersection of cybersecurity and SAP – a domain I know deeply
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
